Search

Emapalumab

Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.

Choline C 11

[A32041] It was developed by MCPRF and FDA first approved in September 2012.

Citrus bioflavonoids

Sodium cellulose phosphate

[A31694] This compound is an ion-exchange resin that can not be absorbed by the body. However, it can be used to restore normal intestinal calcium absorption.

Econazole

It is used topically in dermatomycoses also orally and parenterally.

N-(2-Aminoethyl)-1-aziridineethanamine

First described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease

Repotrectinib

This approval is based on favorable results from the TRIDENT-1 study, where the objective response rate was 79% in TKI-naive patients and 38% in TKI-pretreated patients respectively.[L48741] … Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the

Sevabertinib

[L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608]

Propylthiouracil

It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)

Ripasudil

It was first approved for treatment in Japan in September 2014. This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec.